Suxamethonium, masseter spasm and later malignant hyperthermia

Anaesthesia

Volumn 53, Issue 11, 1998, Pages 1111-1116

  Ramirez R , J A ^a   Cheetham, E D ^a   Laurence, A S ^a   Hopkins, P M ^b  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

^b Malignant Hyperthermia Invest Unit   (United Kingdom)

Author keywords

Hyperthermia; malignant; Neuromuscular relaxants; suxamethonium

Indexed keywords

CREATINE KINASE; DANTROLENE; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; ISOFLURANE; MYOGLOBIN; NEUROMUSCULAR BLOCKING AGENT; SUXAMETHONIUM;

ADULT; ANGIOGRAPHY; ARTICLE; BLOOD LEVEL; BRACHIAL ARTERY; CASE REPORT; CREATINE KINASE BLOOD LEVEL; HUMAN; MALE; MALIGNANT HYPERTHERMIA; MASSETER MUSCLE; MUSCLE SPASM; PATIENT TRANSPORT; RESUSCITATION; THORAX INJURY; URINE LEVEL;

ADULT; ANESTHETICS, INHALATION; HUMANS; ISOFLURANE; MALE; MALIGNANT HYPERTHERMIA; MASSETER MUSCLE; NEUROMUSCULAR DEPOLARIZING AGENTS; SPASM; SUCCINYLCHOLINE;

EID: 0031731659     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2044.1998.00562.x     Document Type: Article

References (12)

1. Larach MG, Rosenberg H, Larach DR, Broennle AM. Prediction of malignant hyperthermia susceptibility by clinical signs. Anesthesiology 1987; 66: 547-50.
2. Laurence AS, Vanner GK, Collins W, Hopkins PM. Serum and urinary myoglobin following an aborted malignant hyperthermia reaction. Anaesthesia 1996; 51: 958-61.
3. Rosenberg H. Clinical presentation of malignant hyperthermia. British Journal of Anaesthesia 1988; 60: 268-73.
4. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. British Journal of Anaesthesia 1984; 56: 1267-9.
5. Hopkins PM, Ellis FR, Halsall PJ. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. British Journal of Anaesthesia 1991; 66: 611-3.
6. Hopkins PM, Halsall PJ, Ellis FR, Stewart AD. An analysis of the predictive probability of the in vitro contracture test for determining malignant hyperthermia susceptibility. Anesthesia and Analgesia 1997; 84: 648-56.
7. Thomas DW, Dev VJ, Whitehead MJ. Malignant hyperpyrexia and isoflurane. A case report. British Journal of Anaesthesia 1986; 59: 1196-8.
8. Rosenberg H, Fletcher JE. Masseter muscle rigidity and malignant hyperthermia susceptibility. Anesthesia and Analgesia 1986; 65: 161-4.
9. Ellis FR, Halsall PJ. Suxamethonium spasm. A differential diagnostic conundrum. British Journal of Anaesthesia 1984; 56: 381-3.
10. Flewellen EH, Nelson TE. Halothane-succinylcholine induced masseter spasm: indicative of malignant hyperthermia susceptibility. Anesthesia and Analgesia 1984; 63: 693-7.
11. Hopkins PM, Ellis FR. Inherited disease affecting anaesthesia. In: Healy TEJ, Cohen PJ, eds. A Practice of Anaesthesia, 6th edn. London: Edward Arnold, 1995: 938-52.
12. Reber A, Schumacher P, Urwyler A. Effects of three different types of management on the elimination kinetics of volatile anaesthetics. Implications for malignant hyperthermia treatment. Anaesthesia 1993; 48: 862-5.